Tests a rapid finger-prick test for HIV, hepatitis B and syphilis
Tests a rapid screening test for HIV, hepatitis B and syphilis in adults.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate Performance, Usability, and Contrived Result Interpretation of TruPlex HIV/HepB/Syphilis Rapid Test
Key facts
- Where
- Cape Town, Durban, and Johannesburg, South AfricaSee the 3 sites
Where in South Africa
- Epicentre Health Research (Cape Town)Cape Town, South AfricaTaking people
- Epicentre Health ResearchDurban, South AfricaTaking people
- Epicentre Health Research (Johannesburg)Johannesburg, South AfricaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- bioLytical Laboratories
- Trial code
- NCT07563309
- Record updated
- 2 October 2026
- Original description
The objectives of this study are as follows:Read full original descriptionShow less
A Study to Evaluate the Performance, Usability, and Contrived Result Interpretation of TruPlex HIV/HepB/Syphilis Rapid Test by Trained Personnel at Near-Patient and Point-of-Care Settings
The objectives of this study are as follows:
To evaluate the clinical performance of the TruPlex test using capillary blood, EDTA whole blood, EDTA plasma, and SST serum samples collected by trained operators in point-of-care settings
To evaluate the usability of the TruPlex test through:
Structured usability assessments, via a questionnaire, completed by trained operators in point-of-care settings.
To assess user interpretation accuracy through a contrived result interpretation questionnaire, where intended users evaluate a set of pre-defined test results (e.g., strong/weak positives, negatives, invalids).
To monitor test system reliability, including invalid rates.
Inclusion: 18 years of age or older; Subject is able to provide and willing to sign and date the Informed Consent Form; Subject is able to complete the required testing on the allocated testing day; Subject able to speak/read/write English or a translator is available; Subject is getting tested for HIV, and/or Syphilis, and/or Hepatitis B for one or more of the following reasons:; At risk for any one of the target diseases; Having signs or symptoms indicative of the target diseases; Routine testing; Note: Subjects who are pregnant and re-infected are eligible to participate; Unknown HIV or known HIV positive status with less than 12 months of Anti-Retroviral Treatment (ART); Subject is willing to provide the fingerstick blood sample(s) and whole blood samples collected through venous blood draw (approximately 16 ml) required for the study; Subject willing to participate in the study site's standard of care counselling and testing program and receive the study site's standard of care test results.
Exclusion: Subject has received any experimental HIV vaccine; Subject received HBV vaccine within the last 7 days; Known HIV positive subjects and currently on ART for 12 months or longer; Subject has a bleeding disorder; Any condition which, in the opinion of the Investigator, would make the participant unsuitable or unsafe for enrolment or could interfere with the completion of study assessment, consent form and questionnaire etc. or bias the study outcome; Subject is currently undergoing Syphilis treatment.